Catalyst's new orphan drug is off to a strong start.
News & Analysis: Catalyst Pharmaceuticals
These biotech stocks could have a lot of room to run.
The drugmaker's Q4 earnings release was a big hit with investors.
CPRX earnings call for the period ending December 31, 2018.
The FDA approval of Catalyst's long-awaited LEMS drug hasn't been kind to its share price. Here's why.
Catalysts' landmark FDA approval wasn't enough to convince investors to stay the course.
The biopharma's shares pushed higher today after the company announced that it has completed its regulatory filing for Firdapse.
Shares of Catalyst Pharmaceuticals bolted higher today by double-digits. Here's why.
Catalyst Pharmaceutical Partners' shareholders discover that two's a crowd.
A look at the biggest stories this week in biotech and what they mean for investors.